Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia

NCT01690065 is registered in ClinicalTrials.gov with Ulsan University Hospital as lead sponsor.

NCT NCT01690065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01690065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia
Lead sponsor
Ulsan University Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2012
Completion date
December 31, 2019
Enrollment
46 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia in myeloid blast crisis, untreated adult acute myeloid leukemia